PeptideStack
5.2kquestions
20kanswers
220users

semaglutide

Page 14 of 15 · 360 questions tagged semaglutide.

360 questions · sorted by votes · page 14 of 15

7 votes0 answers2.8k views
What does ATTAIN-1 actually establish about dulaglutide?

Numbers first: ATTAIN-1 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by eoin_mcgarry 16k · 9 months ago
6 votes4 answers21k views
Does the ATTAIN-1 population resemble anyone asking about orforglipron here?

What I have: ATTAIN-1 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by label_claim 11k · 2.2 years ago
6 votes 5 answers19k views
How comparable are tirzepatide and cagrilintide on the evidence available?

For reference: tirzepatide · cagrilintide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and they…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by rosa_mendieta 13k · 20 months ago
6 votes 3 answers16k views
How comparable are tirzepatide and liraglutide on the evidence available?

For reference: tirzepatide · liraglutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by two_two_micron 15k · 17 months ago
6 votes5 answers15k views
Is SURMOUNT-2 a fair comparison of ecnoglutide against its comparator arm?

The specifics, since they change the answer: SURMOUNT-2 · ecnoglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
thyroid
thyroid

Thyroid questions: the rodent C-cell findings behind the labelled warning, human calcitonin data, TSH drift during weight loss, and the…

14 questions
asked by m_haraldsen 38k · 2.1 years ago
6 votes 5 answers12k views
Why do two papers on STEP 1 report different headline figures?

I have the full paper rather than the abstract, and the supplementary appendix. I can predict the outcome but I cannot explain it, which means I will get the next…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by tri_gly_ala 48k · 22 months ago
6 votes 5 answers11k views
Is PIONEER-1 a fair comparison of survodutide against its comparator arm?

The specifics, since they change the answer: PIONEER-1 · survodutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by mass_shift_18 14k · 21 months ago
6 votes 5 answers8.6k views
Why do two papers on ATTAIN-1 report different headline figures?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I keep seeing this stated as a fact with no explanation…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by mala_venkatesh 21k · 10 months ago
6 votes 3 answers7.3k views
Liraglutide daily versus a weekly agonist — is there still a case?

I would like to know how much of this is established and how much is a reasonable story. I want to know what the trade-off actually is rather than which option is…

liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

14 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
asked by net_peptide 16k · 7 months ago
6 votes5 answers6.8k views
Is ESSENCE a fair comparison of oral semaglutide against its comparator arm?

The case in front of me: ESSENCE · oral semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

14 questions
asked by plate_count_9k 95k · 9 months ago
6 votes 5 answers6.1k views
Does the STEP 2 population resemble anyone asking about dulaglutide here?

Details up front: STEP 2 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by priya_menon 11k · 7 months ago
6 votes 3 answers2.6k views
Does the TRIUMPH-3 population resemble anyone asking about survodutide here?

The particulars: TRIUMPH-3 · survodutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by ekaterina_volk 16k · 33 days ago
6 votes 2 answers2.1k views
What does SURMOUNT-3 actually establish about liraglutide?

Conditions: SURMOUNT-3 · liraglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by area_percent 13k · 8 months ago
6 votes0 answers1.2k views
Does the SURMOUNT-1 population resemble anyone asking about retatrutide here?

Details up front: SURMOUNT-1 · retatrutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

445 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

14 questions
asked by vial_five 15k · 6 months ago
5 votes 5 answers25k views
Why do two papers on SELECT report different headline figures?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. The empirical answer seems settled. The explanation does not. If…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
asked by forty_two_c 43k · 2.1 years ago
5 votes 5 answers24k views
How comparable are ecnoglutide and tirzepatide on the evidence available?

The case in front of me: ecnoglutide · tirzepatide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
renal-outcomes
renal-outcomes

Kidney endpoints: the FLOW composite, eGFR slope as an endpoint, albuminuria regression, and why an early eGFR dip is expected rather than alarming.

14 questions
asked by fib4_reader 35k · 2.0 years ago
5 votes 5 answers20k views
Is REDEFINE-1 a fair comparison of cagrilintide against its comparator arm?

Setup, so nobody has to ask: REDEFINE-1 · cagrilintide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by Dr_Lena_Ostrowska 42k · 20 months ago
5 votes 5 answers12k views
What does PIONEER-4 actually establish about ecnoglutide?

The specifics, since they change the answer: PIONEER-4 · ecnoglutide. I want to understand what this actually establishes, as opposed to what it is being used to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

14 questions
asked by Dr_Marek_Zielinski 39k · 12 months ago
5 votes 5 answers5.3k views
What does STEP 4 actually establish about orforglipron?

What I have: STEP 4 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by s_kalniete 47k · 3 months ago
5 votes0 answers3.2k views
What does SURPASS-2 actually establish about ecnoglutide?

The specifics, since they change the answer: SURPASS-2 · ecnoglutide. I want to understand what this actually establishes, as opposed to what it is being used to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by pip_okonjo 11k · 10 months ago
5 votes0 answers2.6k views
What does SOUL actually establish about orforglipron?

What I have: SOUL · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
asked by mg_per_ml 12k · 9 months ago
4 votes 5 answers22k views
Is SURMOUNT-OSA a fair comparison of ecnoglutide against its comparator arm?

The specifics, since they change the answer: SURMOUNT-OSA · ecnoglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by tenth_of_a_unit 40k · 21 months ago
4 votes0 answers6.4k views
How comparable are liraglutide and survodutide on the evidence available?

For reference: liraglutide · survodutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by priya_menon 11k · 23 months ago
4 votes4 answers6.1k views
Is STEP 8 a fair comparison of oral semaglutide against its comparator arm?

Concretely: STEP 8 · oral semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Has…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
asked by lucia_marchetti 18k · 14 months ago